Comprehensive Pan-Cancer Bioinformatics Analysis Identifies DHX58 as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Tumor Types
- 1Department of Medical Laboratory Technologies, College of Health and Medical Technologies, Southern Technical University, Basrah, Iraq.
- 2Department of Medical Genetics, Bayan National Laboratory for Advanced Medical Diagnostics, Basrah, Iraq.
Abstract
Background:: DExH-box helicase 58 (DHX58/LGP2) is an innate immune regulator with a previously uncharacterized role in oncology. This study evaluates the multifaceted role of the DHX58 gene, examining its pan-cancer expression, prognostic value, and therapeutic potential across various tumor types through an extensive pan-cancer bioinformatics analysis.
Methods: : We conducted a bioinformatics analysis of DHX58 using TCGA and GTEx data from four platforms: GEPIA2, TIMER 2.0, UALCAN, and starBase. We assessed differential expression, prognostic significance and survival outcomes, drug sensitivity, functional enrichment, genomic alterations, protein–protein interactions, and DNA methylation across 32 cancer types.
Results:: Our findings revealed that the differential expression of the DHX58 gene across numerous cancers was context-dependent, with consistent downregulation in lung squamous cell carcinoma and upregulation in head and neck squamous cell carcinoma. Low DHX58 expression correlated with poor survival in kidney chromophobe renal cell carcinoma, sarcoma, and skin melanoma, but with favorable outcomes in other cancers, such as colon adenocarcinoma. Notably, low DHX58 expression was associated with increased sensitivity to birinapant and saracatinib. Genomic alterations were infrequent, and methylation patterns were largely unchanged. Functional enrichment analysis emphasized DHX58’s established role in innate immunity and antiviral responses, with its co-expressed genes implicated in viral defense pathways. Genomic profiling identified various alterations, including mutations and copy number variations, contributing to DHX58 dysregulation. Protein–protein interaction mapping solidified its central role in immune signaling, while DNA methylation analysis highlighted epigenetic regulation as another layer of control.
Conclusion:: Our pan-cancer analysis reveals that DHX58 has context-specific prognostic and predictive roles. While discrepancies between platforms exist, DHX58 emerges as a potential biomarker in specific cancers, particularly in the context of therapies involving agents like birinapant. These findings warrant further mechanistic and clinical investigation.
Related
- Integrative Multi-Database Bioinformatics Characterization of FANCE in Hepatocellular Carcinoma: Prognostic, Epigenetic, Immune, and ncRNA Associations
- Potential role of PDLIM1 in the tumorigenesis of acute myeloid leukemia: a comprehensive bioinformatics and in vitro study
- Expression, prognostic association, and immune microenvironment correlates of C4orf50 in breast cancer: a The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) bioinformatics study
- Identification of SLC15A3 as a shared prognostic biomarker for AML and COVID-19 via integrative bioinformatics, machine learning and Mendelian randomization
- Integrated bioinformatics analysis identifies a ubiquitination-related gene signature in schizophrenia with peripheral clinical validation
BibTeX
@article{aziz2026comprehensive,
title = {{Comprehensive Pan-Cancer Bioinformatics Analysis Identifies DHX58 as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Tumor Types}},
author = {Hussam S Aziz and Ayoob Al-Zaalan},
journal = {Asian Pacific Journal of Cancer Prevention : APJCP},
year = {2026},
month = may,
doi = {10.31557/apjcp.2026.27.6.2117},
url = {https://doi.org/10.31557/apjcp.2026.27.6.2117},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Comprehensive Pan-Cancer Bioinformatics Analysis Identifies DHX58 as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Tumor Types
AU - Hussam S Aziz
AU - Ayoob Al-Zaalan
PY - 2026
DA - 2026/05/22
JO - Asian Pacific Journal of Cancer Prevention : APJCP
DO - 10.31557/apjcp.2026.27.6.2117
UR - https://doi.org/10.31557/apjcp.2026.27.6.2117
AB - Background:: DExH-box helicase 58 (DHX58/LGP2) is an innate immune regulator with a previously uncharacterized role in oncology. This study evaluates the multifaceted role of the DHX58 gene, examining its pan-cancer expression, prognostic value, and therapeutic potential across various tumor types through an extensive pan-cancer bioinformatics analysis. Methods: : We conducted a bioinformatics analysis of DHX58 using TCGA and GTEx data from four platforms: GEPIA2, TIMER 2.0, UALCAN, and starBase. We assessed differential expression, prognostic significance and survival outcomes, drug sensitivity, functional enrichment, genomic alterations, protein–protein interactions, and DNA methylation across 32 cancer types. Results:: Our findings revealed that the differential expression of the DHX58 gene across numerous cancers was context-dependent, with consistent downregulation in lung squamous cell carcinoma and upregulation in head and neck squamous cell carcinoma. Low DHX58 expression correlated with poor survival in kidney chromophobe renal cell carcinoma, sarcoma, and skin melanoma, but with favorable outcomes in other cancers, such as colon adenocarcinoma. Notably, low DHX58 expression was associated with increased sensitivity to birinapant and saracatinib. Genomic alterations were infrequent, and methylation patterns were largely unchanged. Functional enrichment analysis emphasized DHX58’s established role in innate immunity and antiviral responses, with its co-expressed genes implicated in viral defense pathways. Genomic profiling identified various alterations, including mutations and copy number variations, contributing to DHX58 dysregulation. Protein–protein interaction mapping solidified its central role in immune signaling, while DNA methylation analysis highlighted epigenetic regulation as another layer of control. Conclusion:: Our pan-cancer analysis reveals that DHX58 has context-specific prognostic and predictive roles. While discrepancies between platforms exist, DHX58 emerges as a potential biomarker in specific cancers, particularly in the context of therapies involving agents like birinapant. These findings warrant further mechanistic and clinical investigation.
SN - 1513-7368
SN - 2476-762X
ER -